Pre-Exposure Prophylaxis (PrEP) has been recommended by the CDC since 2014 as one option for prevention of HIV transmission in adults at high risk. There is only one FDA approved drug for this indication.
Truvada 200mg/300mg, 1 tab PO daily
[emtricitabine (FTC) 200 mg and tenofovir disoproxil fumarate (TDF) 300 mg]
- Sexually-active adult MSM (men who have sex with men) at substantial risk of HIV acquisition
- Adult heterosexually active men and women who are at substantial risk of HIV acquisition
- Adult persons who inject drugs who are at substantial risk of HIV acquisition
- PrEP should be discussed with heterosexually-active women and men whose partners are known to have HIV infection (i.e., HIV-discordant couples) as one of several options to protect the uninfected partner during conception and pregnancy so that an informed decision can be made in awareness of what is known and unknown about benefits and risks of PrEP for mother and fetus